Sun Pharmaceutical Industries announced that one of its wholly-owned
subsidiaries has launched a novel anti-cancer drug, Palbociclib in India for patients who have advanced breast cancer, the most common cancer among women in the country. The company will make the drug available under the brand name, PALENOTM (Palbociclib) 75 mg, 100 mg, 125
mg.
Palbociclib is approved by the USFDA, EMA and CDSCO in combination with hormonal therapies for patients with hormone receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
